Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.540 |
Why?
|
| HLA-A2 Antigen | 4 | 2018 | 159 | 0.450 |
Why?
|
| Myeloblastin | 3 | 2018 | 64 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3251 | 0.440 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 15694 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 4367 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 6 | 2024 | 4975 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 1016 | 0.240 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 1506 | 0.240 |
Why?
|
| Fetal Blood | 2 | 2016 | 482 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 1215 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2016 | 1146 | 0.190 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 675 | 0.180 |
Why?
|
| Antigen Presentation | 2 | 2018 | 272 | 0.170 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3230 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2019 | 1763 | 0.170 |
Why?
|
| Immunomodulation | 2 | 2018 | 242 | 0.170 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 2864 | 0.160 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 219 | 0.150 |
Why?
|
| Peptide Fragments | 3 | 2018 | 1271 | 0.150 |
Why?
|
| Serine Proteases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2018 | 6915 | 0.150 |
Why?
|
| Cathepsin G | 1 | 2016 | 23 | 0.140 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 84 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 709 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 665 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 582 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2016 | 351 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 202 | 0.120 |
Why?
|
| Neutrophils | 1 | 2018 | 835 | 0.120 |
Why?
|
| Thymus Gland | 1 | 2015 | 294 | 0.120 |
Why?
|
| Arabinonucleosides | 1 | 2016 | 437 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 1033 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 15862 | 0.110 |
Why?
|
| Busulfan | 1 | 2016 | 764 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 577 | 0.100 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 305 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 941 | 0.100 |
Why?
|
| Vidarabine | 1 | 2016 | 1341 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3890 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 2594 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Lymphocyte Activation | 3 | 2019 | 1688 | 0.080 |
Why?
|
| Humans | 15 | 2024 | 261506 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2016 | 2238 | 0.070 |
Why?
|
| Female | 7 | 2024 | 141928 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2015 | 1664 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 992 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2022 | 1062 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 2138 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2359 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 3869 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.070 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1022 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2024 | 32848 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2527 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1681 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 2979 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2016 | 3341 | 0.060 |
Why?
|
| Peptides | 2 | 2019 | 1479 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 14551 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 331 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 429 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 253 | 0.050 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 18 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 213 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 157 | 0.040 |
Why?
|
| Cross-Priming | 1 | 2018 | 39 | 0.040 |
Why?
|
| Complement Activation | 1 | 2018 | 94 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1046 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2018 | 284 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 597 | 0.040 |
Why?
|
| U937 Cells | 1 | 2016 | 171 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 47 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 5047 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 107 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2023 | 1996 | 0.030 |
Why?
|
| Mice | 4 | 2019 | 34495 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 235 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 338 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 2803 | 0.030 |
Why?
|
| Cytokines | 2 | 2017 | 2809 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 589 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 5061 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 11538 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 649 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 733 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 2518 | 0.030 |
Why?
|
| Epitopes | 1 | 2016 | 685 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 1062 | 0.030 |
Why?
|
| Animals | 4 | 2019 | 59536 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2012 | 263 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 1555 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 4233 | 0.020 |
Why?
|
| Adult | 4 | 2018 | 77950 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 287 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 442 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 3536 | 0.020 |
Why?
|
| Pancreas | 1 | 2012 | 718 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 3639 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 3033 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1616 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5114 | 0.020 |
Why?
|
| Testis | 1 | 2012 | 717 | 0.020 |
Why?
|
| Gene Expression | 1 | 2016 | 3570 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5637 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 5395 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 4053 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 4143 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1353 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 1149 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2638 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 6150 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9180 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 6942 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 21713 | 0.010 |
Why?
|
| Middle Aged | 2 | 2023 | 86204 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2012 | 2669 | 0.010 |
Why?
|
| Male | 3 | 2018 | 123000 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 37905 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 21445 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 11965 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2016 | 29154 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.010 |
Why?
|